What does this company do and how does it make money?

ISRG operates a razor-and-blade model where surgical systems drive recurring instrument sales that generate 60% of revenue. The acceleration in procedure growth suggests strong underlying demand, but margin compression during the fastest growth period raises questions about competitive dynamics or strategic trade-offs for market share.

Five legendary investment frameworks analyzed this company.

Marks sees 'asymmetric downside' at 63x earnings while Lynch spots a fast grower entering 'dangerous middle innings' — but the real story is why ISRG took on debt for the first time ever while generating record cash. Tap any framework below to explore their complete analysis and position.

How much cash does it generate and where does it go?

ISRG generates exceptional cash but allocates it erratically — R&D remains the priority while buybacks swing from zero to billions quarter-to-quarter. The company spent $5.3B on buybacks at an average price of $2,171, now underwater at $461, suggesting poor timing despite strong operational cash generation.

Is the business getting stronger or weaker?

The business shows conflicting signals — revenue growth is accelerating to multi-year highs while profitability metrics deteriorate. Operating leverage below 1.0 means each dollar of growth generates proportionally less profit, suggesting either competitive pressure or deliberate margin sacrifice for growth.

What could go wrong and has it survived trouble before?

ISRG proved resilient through COVID's 70% cash flow collapse, recovering within two quarters. But new risks emerge — the first-ever debt assumption coinciding with record profits is unusual, while persistent insider selling during peak performance suggests management sees limited upside at current valuations.

Trading at 63x earnings with insiders dumping shares for 10 consecutive quarters, ISRG asks investors to bet on perfection while the builders cash out.

Is the stock priced for perfection, fair value, or pessimism?

At 63x earnings with a 0.40% yield versus 4.33% treasuries, ISRG requires exceptional growth to justify its premium. The market's implied 10% perpetual growth rate is half the current pace, suggesting investors expect deceleration but still price in flawless execution with asymmetric downside on any disappointment.